[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:angiosarcoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":62,"states":63},"Angiosarcoma",8,6,[8,16,23,29,35,41,47,54],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05607095","A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma",[12],"Phase 1","RECRUITING","2026-08-26T02:18:51.009190Z","2026-07-19T19:36:05.123927Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06239272","NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)",[20],"Phase 1\u002FPhase 2","2026-08-26T02:18:06.247899Z","2026-07-19T19:36:05.068230Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06440005","A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors",[12],"2026-08-26T02:16:20.336282Z","2026-05-05T02:43:29.223313Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT05859074","A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer",[12],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:27.807952Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06113809","Palbociclib and Pembrolizumab in Sarcoma",[12],"2026-08-26T02:17:39.857430Z","2026-05-05T02:35:31.898243Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT00842283","Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target",[],"2026-08-26T02:17:17.791881Z","2026-05-13T02:55:06.064828Z",{"nct_id":48,"title":49,"phases":50,"status":51,"updated_at":52,"content_modified":53},"NCT07389239","A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.",[20],"NOT_YET_RECRUITING","2026-08-26T02:19:15.498463Z","2026-05-05T02:43:29.075289Z",{"nct_id":55,"title":56,"phases":57,"status":59,"updated_at":60,"content_modified":61},"NCT06898970","Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma",[58],"Phase 2","ACTIVE_NOT_RECRUITING","2026-08-03T02:24:39.214133Z","2026-05-05T02:43:27.835418Z",[],[64],{"state":65,"count":66,"slug":67},"California",3,"california"]